Cargando…
Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study
| Autores principales: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522597/ https://www.ncbi.nlm.nih.gov/pubmed/37752114 http://dx.doi.org/10.1038/s41408-023-00923-6 |
| _version_ | 1785110386031198208 |
|---|---|
| author | Martin, Thomas Dimopoulos, Meletios-Athanasios Mikhael, Joseph Yong, Kwee Capra, Marcelo Facon, Thierry Hajek, Roman Špička, Ivan Baker, Ross Kim, Kihyun Martinez, Gracia Min, Chang-Ki Pour, Ludek Leleu, Xavier Oriol, Albert Koh, Youngil Suzuki, Kenshi Casca, France Macé, Sandrine Risse, Marie-Laure Moreau, Philippe |
| author_facet | Martin, Thomas Dimopoulos, Meletios-Athanasios Mikhael, Joseph Yong, Kwee Capra, Marcelo Facon, Thierry Hajek, Roman Špička, Ivan Baker, Ross Kim, Kihyun Martinez, Gracia Min, Chang-Ki Pour, Ludek Leleu, Xavier Oriol, Albert Koh, Youngil Suzuki, Kenshi Casca, France Macé, Sandrine Risse, Marie-Laure Moreau, Philippe |
| author_sort | Martin, Thomas |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10522597 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-105225972023-09-28 Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study Martin, Thomas Dimopoulos, Meletios-Athanasios Mikhael, Joseph Yong, Kwee Capra, Marcelo Facon, Thierry Hajek, Roman Špička, Ivan Baker, Ross Kim, Kihyun Martinez, Gracia Min, Chang-Ki Pour, Ludek Leleu, Xavier Oriol, Albert Koh, Youngil Suzuki, Kenshi Casca, France Macé, Sandrine Risse, Marie-Laure Moreau, Philippe Blood Cancer J Correction Nature Publishing Group UK 2023-09-27 /pmc/articles/PMC10522597/ /pubmed/37752114 http://dx.doi.org/10.1038/s41408-023-00923-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correction Martin, Thomas Dimopoulos, Meletios-Athanasios Mikhael, Joseph Yong, Kwee Capra, Marcelo Facon, Thierry Hajek, Roman Špička, Ivan Baker, Ross Kim, Kihyun Martinez, Gracia Min, Chang-Ki Pour, Ludek Leleu, Xavier Oriol, Albert Koh, Youngil Suzuki, Kenshi Casca, France Macé, Sandrine Risse, Marie-Laure Moreau, Philippe Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study |
| title | Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study |
| title_full | Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study |
| title_fullStr | Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study |
| title_full_unstemmed | Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study |
| title_short | Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study |
| title_sort | correction: isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from ikema, a randomized phase 3 study |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522597/ https://www.ncbi.nlm.nih.gov/pubmed/37752114 http://dx.doi.org/10.1038/s41408-023-00923-6 |
| work_keys_str_mv | AT martinthomas correctionisatuximabcarfilzomibanddexamethasoneinpatientswithrelapsedmultiplemyelomaupdatedresultsfromikemaarandomizedphase3study AT dimopoulosmeletiosathanasios correctionisatuximabcarfilzomibanddexamethasoneinpatientswithrelapsedmultiplemyelomaupdatedresultsfromikemaarandomizedphase3study AT mikhaeljoseph correctionisatuximabcarfilzomibanddexamethasoneinpatientswithrelapsedmultiplemyelomaupdatedresultsfromikemaarandomizedphase3study AT yongkwee correctionisatuximabcarfilzomibanddexamethasoneinpatientswithrelapsedmultiplemyelomaupdatedresultsfromikemaarandomizedphase3study AT capramarcelo correctionisatuximabcarfilzomibanddexamethasoneinpatientswithrelapsedmultiplemyelomaupdatedresultsfromikemaarandomizedphase3study AT faconthierry correctionisatuximabcarfilzomibanddexamethasoneinpatientswithrelapsedmultiplemyelomaupdatedresultsfromikemaarandomizedphase3study AT hajekroman correctionisatuximabcarfilzomibanddexamethasoneinpatientswithrelapsedmultiplemyelomaupdatedresultsfromikemaarandomizedphase3study AT spickaivan correctionisatuximabcarfilzomibanddexamethasoneinpatientswithrelapsedmultiplemyelomaupdatedresultsfromikemaarandomizedphase3study AT bakerross correctionisatuximabcarfilzomibanddexamethasoneinpatientswithrelapsedmultiplemyelomaupdatedresultsfromikemaarandomizedphase3study AT kimkihyun correctionisatuximabcarfilzomibanddexamethasoneinpatientswithrelapsedmultiplemyelomaupdatedresultsfromikemaarandomizedphase3study AT martinezgracia correctionisatuximabcarfilzomibanddexamethasoneinpatientswithrelapsedmultiplemyelomaupdatedresultsfromikemaarandomizedphase3study AT minchangki correctionisatuximabcarfilzomibanddexamethasoneinpatientswithrelapsedmultiplemyelomaupdatedresultsfromikemaarandomizedphase3study AT pourludek correctionisatuximabcarfilzomibanddexamethasoneinpatientswithrelapsedmultiplemyelomaupdatedresultsfromikemaarandomizedphase3study AT leleuxavier correctionisatuximabcarfilzomibanddexamethasoneinpatientswithrelapsedmultiplemyelomaupdatedresultsfromikemaarandomizedphase3study AT oriolalbert correctionisatuximabcarfilzomibanddexamethasoneinpatientswithrelapsedmultiplemyelomaupdatedresultsfromikemaarandomizedphase3study AT kohyoungil correctionisatuximabcarfilzomibanddexamethasoneinpatientswithrelapsedmultiplemyelomaupdatedresultsfromikemaarandomizedphase3study AT suzukikenshi correctionisatuximabcarfilzomibanddexamethasoneinpatientswithrelapsedmultiplemyelomaupdatedresultsfromikemaarandomizedphase3study AT cascafrance correctionisatuximabcarfilzomibanddexamethasoneinpatientswithrelapsedmultiplemyelomaupdatedresultsfromikemaarandomizedphase3study AT macesandrine correctionisatuximabcarfilzomibanddexamethasoneinpatientswithrelapsedmultiplemyelomaupdatedresultsfromikemaarandomizedphase3study AT rissemarielaure correctionisatuximabcarfilzomibanddexamethasoneinpatientswithrelapsedmultiplemyelomaupdatedresultsfromikemaarandomizedphase3study AT moreauphilippe correctionisatuximabcarfilzomibanddexamethasoneinpatientswithrelapsedmultiplemyelomaupdatedresultsfromikemaarandomizedphase3study |